Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
ID: 351613Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $30M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351613
Timeline
    Description

    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the TrialNet Coordinating Center (TNCC), which is part of the TrialNet network. The TNCC plays a crucial role in identifying individuals with type 1 diabetes (T1D) at different stages of the disease and enrolling them in trials and studies aimed at preventing the progression of clinical symptoms and preserving insulin production. The TNCC supports various research projects, manages data and samples, and oversees network administration and operations. The TNCC will also be responsible for evaluating, selecting, and funding Clinical Centers and central support units necessary for TrialNet's clinical studies. The TNCC PD/PI will be a voting member of the TrialNet Executive and Steering Committees. The funding opportunity announcement is expected to be published in Spring 2024, with an application due date in Summer 2024. The TNCC will be funded through a cooperative agreement, and the estimated total program funding is $29,500,000.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), aimed at enhancing clinical trials focused on the prevention and early intervention of Type 1 Diabetes (T1D). The HUB will coordinate operations across various clinical centers to improve participant screening, recruitment, and retention, with a specific emphasis on increasing diversity among participants, particularly from minority populations. This initiative is critical for addressing the rising incidence of T1D and ensuring inclusivity in research efforts. The funding opportunity has an estimated budget of $750,000 per year from a total allocation of $1,000,000, with a maximum project duration of five years. Applications will be accepted starting September 16, 2024, and must include a Plan for Enhancing Diverse Perspectives (PEDP) to be considered complete. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition for the Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Limited Competition Funding Opportunity titled "Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers" (T1DAPC-CCs), aimed at establishing a clinical consortium to study diabetes incidence following acute pancreatitis episodes, with a focus on type 1 diabetes. This initiative seeks applications from previously funded Clinical Centers to continue a longitudinal observational study that investigates the incidence, etiology, and risk factors associated with diabetes emerging after acute pancreatitis, emphasizing collaboration among consortium members and effective data collection strategies. The funding amount is capped at $350,000 annually, with a project timeline extending up to five years, and applications are due by November 19, 2024, with the earliest anticipated award start in July 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Single Source for the Continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for a cooperative agreement to establish the Type 1 Diabetes in Acute Pancreatitis Consortium Data Coordinating Center (T1DAPC-DCC). The primary objective is to conduct a longitudinal observational study, known as the DREAM study, which will investigate the incidence and mechanisms of diabetes that develop following episodes of acute pancreatitis. This initiative is crucial for understanding the relationship between acute pancreatitis and the onset of diabetes, particularly type 1 diabetes, and aims to identify genetic and environmental risk factors in a diverse population. Interested applicants must submit their proposals by November 19, 2024, with a funding ceiling of $800,000, and can direct inquiries to grantsinfo@nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the establishment of a Data Management and Coordinating Center (DMCC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases by facilitating collaborative, multi-site, patient-centric research through the RDCRN and supporting the activities of the Rare Diseases Clinical Research Consortia (RDCRC). The estimated total program funding for this grant is $1,000,000, with the FOA expected to be published in 2024 and awards anticipated in 2025. Interested applicants can reach out to Dr. Tiina K. Urv at urvtiin@mail.nih.gov or by phone at 301-827-2746 for further information.
    The Chronic Pancreatitis Clinical Research Consortium (CPCRC)- Clinical Centers (CPCRC-CCs) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Chronic Pancreatitis Clinical Research Consortium (CPCRC), inviting U01 applications for Clinical Centers to conduct research on chronic pancreatitis, diabetes, and pancreatic cancer. The initiative aims to continue the consortium's work by collecting clinical data and biospecimens to identify biomarkers for risk stratification and disease progression, ultimately enhancing understanding and treatment of these conditions. With an estimated funding of $6.5 million for the 2025 fiscal year, applications are due by October 18, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Single Source for Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC-DCC) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement for the establishment of the Chronic Pancreatitis Clinical Research Consortium Data Coordinating Center (CPCRC-DCC) under funding opportunity RFA-DK-25-020. The primary objective is to facilitate ongoing studies on chronic pancreatitis, diabetes, and pancreatic cancer, focusing on data management, biomarker development, and clinical trial support for both pediatric and adult populations. This initiative is crucial for advancing the understanding of chronic pancreatitis and its associations with diabetes and pancreatic cancer, with an anticipated funding amount of $6.5 million over five years. Interested applicants must submit their proposals by 5:00 PM on October 19, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network (NCTN) - Network Group Operations Centers, which will require a U10 clinical trial. This initiative aims to provide scientific leadership for the development and implementation of multi-disciplinary, multi-institutional clinical trials targeting various cancer types and populations, focusing on late-phase treatment trials and advanced imaging studies. The funding, estimated at $99.3 million, is intended to support the conduct of essential clinical research for adults, adolescents, and children with cancer, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, applicants should prepare their submissions in advance of the anticipated award date of March 1, 2026.